Cartesian Therapeutics

(NASDAQ) RNAC

Current Price$7.39

Market Cap$216.84M

Since IPO (2023)-77%

5 Year-83%

1 Year-29%

1 Month+23%

Cartesian Therapeutics Financials at a Glance

Market Cap

$216.84M

Revenue (TTM)

$1.77M

Net Income (TTM)

$151.77M

EPS (TTM)

$-5.80

P/E Ratio

-1.27

Dividend

$0.00

Beta (Volatility)

1.61 (High)

Dividend

$0.00

Beta (Volatility)

1.61 (High)

Price

$7.39

Volume

4,911

Open

$8.29

Price

$7.39

Volume

4,911

Open

$8.29

Previous Close

$7.39

Daily Range

$7.36 - $8.29

52-Week Range

$5.60 - $15.57

Dividend

$0.00

Beta (Volatility)

1.61 (High)

Price

$7.39

Volume

4,911

Open

$8.29

Previous Close

$7.39

Daily Range

$7.36 - $8.29

52-Week Range

$5.60 - $15.57

RNAC News

Cartesian (RNAC) Q2 Revenue Drops 99%

Motley Fool Markets TeamAug 7, 2025

RNAC: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cartesian Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Carsten Brunn, PhD

Website

www.cartesiantherapeutics.com

Headquarters

Watertown, MA 02472, US

RNAC Financials

Key Financial Metrics (TTM)

Gross Margin

-6%

Operating Margin

-51%

Net Income Margin

-86%

Return on Equity

Return on Capital

-34%

Return on Assets

-53%

Earnings Yield

-78.74%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$216.84M

Shares Outstanding

29.38M

Volume

4.91K

Avg. Volume

210.75K

Financials (TTM)

Gross Profit

$2.80M

Operating Income

$86.70M

EBITDA

$86.70M

Operating Cash Flow

$73.94M

Capital Expenditure

$5.45M

Free Cash Flow

$79.39M

Cash & ST Invst.

$125.14M

Total Debt

$12.68M

Cartesian Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$78.00K

-92.9%

Gross Profit

$78.00K

-92.9%

Gross Margin

100.00%

N/A

Market Cap

$216.84M

N/A

Market Cap/Employee

$3.29M

N/A

Employees

N/A

Net Income

$39.18M

-121.2%

EBITDA

$26.50M

-27.8%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$106.79M

-35.8%

Accounts Receivable

$261.00K

-85.2%

Inventory

$0.00

N/A

Long Term Debt

$7.67M

-26.0%

Short Term Debt

$4.19M

+13.0%

Return on Assets

-52.63%

N/A

Return on Invested Capital

-33.52%

N/A

Free Cash Flow

$22.16M

+8.4%

Operating Cash Flow

$22.14M

+4.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

OBIOOrchestra BioMed Holdings, Inc.

OBIOOrchestra BioMed Holdings, Inc.$3.72-9.49%

EPRXEupraxia Pharmaceuticals Inc.

EPRXEupraxia Pharmaceuticals Inc.$6.92-3.35%

AVTXAvalo Therapeutics, Inc.

AVTXAvalo Therapeutics, Inc.$17.74-6.68%

MDWDMediWound Ltd.

MDWDMediWound Ltd.$16.41-2.29%

FENCFennec Pharmaceuticals Inc.

FENCFennec Pharmaceuticals Inc.$9.75+5.52%

IVAInventiva S.A.

IVAInventiva S.A.$5.44-1.98%

NAUTNautilus Biotechnology, Inc.

NAUTNautilus Biotechnology, Inc.$2.51-4.20%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$10.62-0.05%

INTCIntel

INTCIntel$108.77-0.06%

NOKNokia

NOKNokia$13.95-0.04%

FFord Motor Company

FFord Motor Company$13.40-0.07%

POETPoet Technologies

POETPoet Technologies$15.97-0.22%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$15.06-0.10%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$75.34-0.05%

Questions About RNAC

What is the current price of Cartesian Therapeutics?

Cartesian Therapeutics is trading at $7.39 per share.

What is the 52-week range for Cartesian Therapeutics?

Over the past 52 weeks, Cartesian Therapeutics has traded between $5.60 and $15.57.

How much debt does Cartesian Therapeutics have?

As of the most recent reporting period, Cartesian Therapeutics reported total debt of $11.86M.

How much cash does Cartesian Therapeutics have on hand?

Cartesian Therapeutics reported $118.64M in cash and cash equivalents in its most recent financial results.

What is Cartesian Therapeutics’s dividend yield?

Cartesian Therapeutics does not currently have a dividend yield.

Cartesian Therapeutics

Cartesian Therapeutics Financials at a Glance

RNAC News

Cartesian (RNAC) Q2 Revenue Drops 99%

RNAC: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Cartesian Therapeutics

RNAC Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Cartesian Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About RNAC

What is the current price of Cartesian Therapeutics?

What is the 52-week range for Cartesian Therapeutics?

How much debt does Cartesian Therapeutics have?

How much cash does Cartesian Therapeutics have on hand?

What is Cartesian Therapeutics’s dividend yield?

Premium Investing Services